These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma. Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772 [TBL] [Abstract][Full Text] [Related]
3. Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma. Wu KL; Heule F; Lam K; Sonneveld P J Am Acad Dermatol; 2006 Nov; 55(5):897-900. PubMed ID: 17052502 [TBL] [Abstract][Full Text] [Related]
4. Cutaneous lesion induced by a subcutaneous administration of bortezomib. Obeid KM; Ferrara R; Sharma M Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):284-6. PubMed ID: 22633164 [No Abstract] [Full Text] [Related]
5. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report. Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852 [TBL] [Abstract][Full Text] [Related]
11. Bortezomib-induced severe hepatitis in multiple myeloma: a case report. Rosiñol L; Montoto S; Cibeira MT; Bladé J Arch Intern Med; 2005 Feb; 165(4):464-5. PubMed ID: 15738379 [TBL] [Abstract][Full Text] [Related]
12. Skin lesions induced by bortezomib. Pour L; Hajek R; Zdenek A; Krejci M; Krivanova A; Vorlicek J Haematologica; 2005 Dec; 90(12 Suppl):ECR44. PubMed ID: 16464759 [TBL] [Abstract][Full Text] [Related]
13. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma]. Tobinai K Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092 [No Abstract] [Full Text] [Related]
14. Pseudomembranous colitis following bortezomib therapy in a myeloma patient. Moon SJ; Min CK; Lee DG; Lee S; Lee JW; Min WS; Kim CC; Kim M; Park G; Kim Y Acta Haematol; 2007; 117(4):211-4. PubMed ID: 17237615 [TBL] [Abstract][Full Text] [Related]
15. Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines. Min CK; Lee S; Kim YJ; Eom KS; Lee JW; Min WS; Kim CC; Cho CS; Park G Eur J Haematol; 2006 Mar; 76(3):265-8. PubMed ID: 16451401 [TBL] [Abstract][Full Text] [Related]
16. Lupus tumidus induced by bortezomib not requiring discontinuation of the drug. Aguayo-Leiva I; Vano-Galvan S; Carrillo-Gijon R; Jaén-Olasolo P J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1363-4. PubMed ID: 20337821 [No Abstract] [Full Text] [Related]